(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 October 2011 (20.10.2011)

PCT

(10) International Publication Number
WO 2011/130249 A2

(51) International Patent Classification:
A61K 39/395 (2006.01) *C12N 5/09* (2010.01)
A61K 39/00 (2006.01) *A61P 35/00* (2006.01)
C07K 16/00 (2006.01)

(21) International Application Number:
PCT/US2011/032090

(22) International Filing Date:
12 April 2011 (12.04.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/323,557 13 April 2010 (13.04.2010) US

(71) Applicant *(for all designated States except US)*: **IMMUNOVATIVE THERAPIES, LTD.** [IL/IL]; POB 974, 60850 Shoham (IL).

(72) Inventor; and
(75) Inventor/Applicant *(for US only)*: **HAR-NOY, Michael** [US/IL]; 22-1 Emek Zebulun, 71700 Modiin (IL).

(74) Agents: **SAWICKI, Peter, Z.** et al.; Westman, Champlin & Kelly, P.A., 900 Second Avenue South, Suite 1400, Minneapolis, MN 55402-3319 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title**: METHODS AND COMPOSITIONS FOR INHIBITION OF TREG CELLS




FIG. 1A




FIG. 1B

(57) **Abstract**: The present invention relates to methods of suppressing the immune tolerance of a disease or disease antigens in a patient. The method also promotes the activity of the effectore T lymphocytes. The invention includes administering a therapeutic composition that promotes a Th1 environment in the patient while decreasing the immunosuppressive activity of Treg cells that can lead to disease antigen tolerance and immunoavoidance of the disease antigens by the patient. The therapeutic composition includes allogeneic emTh-1 cells. The therapeutic composition can also include disease antigens such as the chaperone-rich cell lysate of the disease antigen.

WO 2011/130249 A2